Imugene Limited (IMU) SWOT Profile

  • April 2010
  • -
  • Global Data

Imugene Limited (IMU) SWOT Profile

Summary

GlobalData’s Imugene Limited (IMU) SWOT Profile is a comprehensive business, functional and strategic analysis of Imugene Limited. The profile delves into the operations of the company to present an in-depth analysis of the various aspects related to its business. It analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, executive biographies and key competitors. The hallmark of the profile is the detailed strategic analysis of the company. This highlights and presents an unbiased view of its key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by understanding your partners, customers and competitors better.

Imugene Limited (Imugene) is a biotechnology company that focuses on the research, development and commercialization of animal health products and technologies in Australia. It specializes in the development and commercialization of novel animal health products for pigs and poultry, including vaccines and productivity enhancers. The company develops vaccines for the prevention of important livestock diseases and productivity enhancers to improve the economics of raising commercial livestock.


Scope

- Examines key information about company for business intelligence.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented objectively. Business, strategic and operational aspects are taken into account.
- Opportunities available to the company are sized up and its growth potential assessed. Competitive and/or technological threats are highlighted.
- The profile contains valuable and critical company information – business structure and operations, the company history, major products and services, prospects, key competitors, key employees, executive biographies, important locations and subsidiaries.
- The profile provides detailed financial ratios for the past five years as well as interim ratios for the last five interim periods for major public companies.
- Financial ratios presented for major public companies include revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Note: Some of the elements mentioned above will be included in the profile based on the availability of information.


Reasons to Buy

- A quick “one-stop-shop” to understand the company clearly.
- Get detailed and exhaustive information and operational & strategic analysis on companies operating in your industry.
- Enhance business/sales activities by understanding customers’ businesses better.
- Identify prospective partners and suppliers – with key data on their businesses and locations.
- Understand and respond to your competitors’ business structure, strategies, and explore weaknesses.
- With key historical ratios, compare your company’s financial trends with those of your competitors.
- Scout for potential acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Table Of Contents

Table of Contents
Table of Contents 2
List of Tables 3


List of Figures 3
Imugene Limited - Key Facts 4
Imugene Limited - Business Description 4
Imugene Limited - Major Products and Services 5
Imugene Limited - History 6
Imugene Limited - SWOT Analysis 7
SWOT Analysis - Overview 7
Imugene Limited - Strengths 7
Strength - Strong patent portfolio 7
Strength - Sturdy Research and Development Activities 7
Strength - Focus on Emerging Market 7
Imugene Limited - Weaknesses 7
Weakness - Limited Geographic Presence 7
Imugene Limited - Opportunities 7
Opportunity - Strategic Alliance 7
Opportunity - Launch of PRRS and Coccidiosis Vaccines 8
Opportunity - Biotech Focus 8
Imugene Limited - Threats 8
Threat - Tightening of FDA’s Regulatory Oversight 8
Threat - Industry consolidation 8
Imugene Limited - Key Competitors 9
Imugene Limited - Key Employees 9
Imugene Limited - Key Employee Biographies 10
Imugene Limited - Company Statement 11
Imugene Limited - Locations And Subsidiaries 13
Head Office 13
Other Locations and Subsidiaries 13
Imugene Limited - Financial Ratios 14
Financial Ratios - Capital Market Ratios 14
Financial Ratios - Annual Ratios 14
Financial Ratios - Interim Ratios 15
Financial Ratios - Ratio Charts 16
Appendix 17
Methodology 17
Ratio Definitions 17
About GlobalData 22
Contact Us 22
Disclaimer 22

List of Tables
Imugene Limited, Key Information 1
Imugene Limited, Key Ratios 1
Imugene Limited, Share Data 1
Imugene Limited, SWOT Analysis 1
Imugene Limited, Key Facts 4
Imugene Limited, Major Products and Services 5
Imugene Limited, History 6
Imugene Limited, Key Employees 9
Imugene Limited, Key Employee Biographies 10
Imugene Limited, Other Locations 13
Imugene Limited, Ratios based on current share price 14
Imugene Limited, Annual Ratios 14
Imugene Limited, Interim Ratios 15
Currency Codes 17
Capital Market Ratios 17
Equity Ratios 18
Profitability Ratios 19
Cost Ratios 20
Liquidity Ratios 20
Leverage Ratios 20
Efficiency Ratios 21

List of Figures
Imugene Limited, Performance Chart (2005 - 2009) 1
Imugene Limited, Ratio Charts 16

Companies Mentioned
The following companies are the major competitors of Imugene Limited:
ProStrakan Group plc
Sigma Pharmaceuticals Limited
BioDiem Ltd
Genetic Technologies Group
Ascent Pharmahealth Limited

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

H5N1 Infection (Avian Influenza) - Pipeline Review, H1 2014

H5N1 Infection (Avian Influenza) - Pipeline Review, H1 2014

  • $ 2 000
  • Company report
  • June 2014
  • by Global Markets Direct

H5N1 Infection (Avian Influenza) - Pipeline Review, H1 2014 Summary Global Markets Direct's, ‘H5N1 Infection (Avian Influenza) - Pipeline Review, H1 2014', provides an overview of the H5N1 Infection ...

Clovis Oncology, Inc. - Product Pipeline Review - 2014

Clovis Oncology, Inc. - Product Pipeline Review - 2014

  • $ 1 500
  • Company report
  • April 2014
  • by Global Markets Direct

Clovis Oncology, Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct's, ‘Clovis Oncology, Inc. - Product Pipeline Review - 2014', provides an overview of the Clovis Oncology, Inc.'s pharmaceutical ...

General Medicine and Specialty Medicine in United States: ZIOPHARM Oncology, Inc. – Product Pipeline Review – H2 2011

General Medicine and Specialty Medicine in United States: ZIOPHARM Oncology, Inc. – Product Pipeline Review – H2 2011

  • $ 1 500
  • Company report
  • July 2014
  • by Global Markets Direct

- Product Pipeline Review - H2 2011” provides a detailed overview on the ZIOPHARM Oncology, Inc.’s research and development focus. The report includes data on current developmental pipeline, complete ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.